Studies foslevodopa/foscarbidopa in adults with early advanced Parkinson's disease
Looks at foslevodopa/foscarbidopa in adults with early advanced Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Key facts
- Where
- Allensbach, Bottrop, Bremen, Cologne, Detmold, Dortmund, Dresden, Erlangen, Gera, Halle, Heidelberg, Ingolstadt, Marburg, Munich, Potsdam, Stadtroda, Tübingen, Ulm, and Wolfach, GermanySee the 19 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 67 years old?
Source: NCT06916507, who can take part
Where in Germany
- Kliniken Schmieder - Allensbach /ID# 285402Allensbach, GermanyTaking people
- Knappschaftskrankenhaus Bottrop /ID# 274284Bottrop, GermanyTaking people
- Klinikum Bremen-Nord /ID# 275822Bremen, GermanyTaking people
- Cellitinnen-NTC Neurologisches Therapiecentrum /ID# 277865Cologne, GermanyTaking people
- Klinikum Lippe Detmold /ID# 279451Detmold, GermanyTaking people
- Klinikum Dortmund Klinikzentrum Mitte /ID# 280222Dortmund, GermanyTaking people
- Universitaetsklinikum Carl Gustav Carus Dresden /ID# 274167Dresden, GermanyTaking people
- Universitaetsklinikum Erlangen /ID# 280831Erlangen, GermanyTaking people
- Praxis MD Oehlwein /ID# 274222Gera, GermanyTaking people
- Krankenhaus Martha-Maria Halle-Dolau /ID# 274174Halle, GermanyTaking people
- Universitaetsklinikum Heidelberg /ID# 274164Heidelberg, GermanyTaking people
- Klinikum Ingolstadt /ID# 280573Ingolstadt, GermanyTaking people
- Universitaetskliniken Giessen und Marburg /ID# 274224Marburg, GermanyTaking people
- Klinikum der Universitaet Muenchen Grosshadern /ID# 274168Munich, GermanyTaking people
- Klinikum Ernst von Bergmann /ID# 274176Potsdam, GermanyTaking people
- Asklepios Fachklinikum Stadtroda /ID# 274162Stadtroda, GermanyTaking people
- Universitaetsklinikum Tuebingen /ID# 275828Tübingen, GermanyTaking people
- Praxis Prof. Kassubek/Prof. Riecker /ID# 274165Ulm, GermanyTaking people
- Parkinson-Klinik Ortenau GmbH&Co KG /ID# 274161Wolfach, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT06916507
- Record updated
- 2 October 2026
- Original description
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective foscarbidopa/ foslevodopa is in treating German adult participants at initial stages of advanced Parkinson's disease under routine clinical practice.Read full original descriptionShow less
German Real-World Evidence Study on the Effectiveness of Foslevodopa/Foscarbidopa at Initial Stages of Advanced Parkinson's Disease: Motor Symptoms, Quality of Life, Psychosocial Functioning and Work Ability
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective foscarbidopa/ foslevodopa is in treating German adult participants at initial stages of advanced Parkinson's disease under routine clinical practice.
Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 125 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 20 sites in Germany.
Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 12 months.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion: Participants with a diagnosis of levodopa-responsive idiopathic Parkinson's disease; Eligibility for foscarbidopa/foslevodopa (LDp/CDp) therapy in accordance with the approved local label; Participant must be an adult male or female, 18-67 years of age; Time since beginning of motor fluctuations <= 5 years; The Hoehn and Yahr (H\&Y) stage <= 3; Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in this study.
Exclusion: Previous Exposure to any device-aided therapy (DAT); Any condition included in the contraindications section of the approved local LDp/CDp label; Participants with Mini mental state examination (MMSE) score < 24.